Lynn Seely

Lynn Seely, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Lyell Immunopharma, Inc. and Blueprint Medicines Corp. The record holds 16 filings, for trades running from 2 June 2021 to 21 August 2026.

Market trades split into 1 purchase (€98k) and 5 sales (€288k). The net balance comes to €190k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 9 share grants. In 2026 alone, the filings show no purchases and 3 sales.

The latest filing, published on 25 August 2026, reports an open-market sale of €127k in Lyell Immunopharma, Inc. The last purchase on record was published on 18 March 2025, which is 579 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.